Skip to main content

Table 3 Spirometry endpoints (full analysis set)

From: Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study)

Endpoint Treatment Baseline value, mean Change from baseline
LS mean (95 % CI) LS mean difference (95 % CI)
Peak IC on Day 1, L IND/GLY 2.36 0.46 (0.42, 0.49) 0.26 (0.22, 0.30); p < 0.0001
Placebo 2.39 0.20 (0.17, 0.24)
Trough IC after 21 days, L IND/GLY 2.36 0.11 (0.07,0.16) 0.20 (0.15, 0.25); p < 0.0001
Placebo 2.40 -0.09 (-0.13, -0.04)
Peak FEV1 on Day 1, L IND/GLY 1.57 0.34 (0.31, 0.37) 0.22 (0.19, 0.25); p < 0.0001
Placebo 1.59 0.12 (0.09, 0.15)
Peak FEV1 after 21 days, L IND/GLY 1.57 0.42 (0.39, 0.45) 0.37 (0.33, 0.40; p < 0.0001)
Placebo 1.59 0.05 (0.02, 0.09)
Trough FEV1 after 21 days, L IND/GLY 1.57 0.20 (0.17, 0.23) 0.28 (0.24, 0.31); p < 0.0001
Placebo 1.60 -0.08 (-0.11, -0.05)